These highlights do not include all the information needed to use FILKRI safely and effectively. See full prescribing information for FILKRI. FILKRI® (filgrastim-laha) injection, for subcutaneous or intravenous use Initial U.S. Approval: 20XX FILKRI (filgrastim-laha) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of FILKRI has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to NEUPOGEN® (filgrastim).

Patient Home

Welcome to Health Vidya. Discover trusted care and your own health — all in one place.

These highlights do not include all the information needed to use FILKRI safely and effectively. See full prescribing information for FILKRI. FILKRI® (filgrastim-laha) injection, for subcutaneous or intravenous use Initial U.S. Approval: 20XX FILKRI (filgrastim-laha) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of FILKRI has been demonstrated for the condition(s) of use (e.g. indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to NEUPOGEN® (filgrastim).

Medication label

Why this: Advisory · dailymed-prescription

FILKRI is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever [see Clinical Studies (14.1)]. FILKRI is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) [see Clinical Studies (14.2)]. FILKRI is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation [see Clinical Studies (14.3)]. FILKRI is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia [see Clinical Studies (14.5)]. FILKRI is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation [see Clinical Studies (14.6)].

generic_name: filgrastim-laha
product_names: filgrastim-laha
ndc: 69448-008, 69448-009, 69448-008-03, 69448-008-63, 69448-009-03, 69448-009-63
group: drugs
license: us-gov-pd
attribution: Courtesy of the National Library of Medicine
reviewed: 2026-09-18
language: en